Cargando…

Initiation And Persistence With Antiplatelet Agents Among The Patients With Acute Coronary Syndromes: A Retrospective, Observational Database Study In China

OBJECTIVES: To investigate the initiation and persistence of antiplatelet agents and the associated factors for patients with acute coronary syndromes (ACS) in Tianjin, China. METHODS: Data were obtained from Tianjin Urban Employee Basic Medical Insurance database (2011–2015). Adult patients who wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xin, He, Xiaoning, Wu, Jing, Luo, Da
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925556/ https://www.ncbi.nlm.nih.gov/pubmed/31908423 http://dx.doi.org/10.2147/PPA.S228065

Ejemplares similares

Trends of prescribing adherence of antiplatelet agents in Hong Kong patients with acute coronary syndrome: a 10-year retrospective observational cohort study
por: Lam, Amy SM, et al.
Publicado: (2020)

Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes
por: Tayeb, Hussam M, et al.
Publicado: (2010)

Insulin adherence and persistence among Chinese patients with type 2 diabetes: a retrospective database analysis
por: He, Xiaoning, et al.
Publicado: (2017)

When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?
por: Silva, Pedro Gabriel Melo de Barros e, et al.
Publicado: (2016)

Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study
por: Claeys, Marc J., et al.
Publicado: (2017)

Novel Antiplatelet Agent Use for Acute Coronary Syndrome in the Emergency Department: A Review
por: Curial, M., et al.
Publicado: (2013)

Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome
por: Kim, Kibum, et al.
Publicado: (2018)

Secondary prevention of acute coronary syndrome with antiplatelet agents in real life: A high-dimensional propensity score matched cohort study in the French National claims database
por: Blin, Patrick, et al.
Publicado: (2020)

Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland
por: Prami, Tuire, et al.
Publicado: (2016)

Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013)

Patterns of antiplatelet agent use in the US
por: Kanakadandi, Vijay, et al.
Publicado: (2015)

Editorial: Antiplatelet Agents in Stroke Prevention
por: Feher, Gergely, et al.
Publicado: (2021)

Antiplatelet therapy in patients with Covid-19: A retrospective observational study
por: Banik, Jozef, et al.
Publicado: (2021)

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010)

Antiplatelet therapy for elderly patients with Acute Coronary Syndromes
por: Savonitto, Stefano, et al.
Publicado: (2018)

Duration of dual antiplatelet therapy in acute coronary syndrome
por: Wilson, Simon John, et al.
Publicado: (2017)

Antiplatelet Therapy and Percutaneous Coronary Interventions
por: Davanzo, Rene Hameau, et al.
Publicado: (2021)

Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry
por: Marcucci, Rossella, et al.
Publicado: (2019)

Newer agents in antiplatelet therapy: a review
por: Yeung, Jennifer, et al.
Publicado: (2012)

Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019
por: Serrano Jr., Carlos V., et al.
Publicado: (2019)

Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments
por: Zeymer, Uwe
Publicado: (2013)

Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome
por: Berger, Jeffrey S.
Publicado: (2018)

Intensity of antiplatelet therapy and percutaneous coronary intervention
por: Aronow, Wilbert S
Publicado: (2009)

Dual Antiplatelet Therapy in Coronary Artery Disease
por: Sharma, Raghav, et al.
Publicado: (2020)

Effectiveness and safety of direct oral anticoagulants with antiplatelet agents in patients with venous thromboembolism: A multi‐database cohort study
por: Douros, Antonios, et al.
Publicado: (2022)

The “Dual-Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial
por: Cohen, Marc, et al.
Publicado: (2014)

Multiple Antiplatelet Therapy in Ischemic Stroke Already on Antiplatelet Agents Based on the Linked Big Data for Stroke
por: Kim, Tae Jung, et al.
Publicado: (2023)

Incidence and Risk Factors for Antiplatelet Therapy–Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation
por: Qian, Yanxia, et al.
Publicado: (2021)

Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain)
por: Ribera, Aida, et al.
Publicado: (2019)

Antiplatelet and Antithrombin Strategies in Acute Coronary Syndrome: State-Of-The-Art Review
por: Showkathali, Refai, et al.
Publicado: (2012)

Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes
por: De Rosa, Roberta, et al.
Publicado: (2019)

Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective
por: Tersalvi, Gregorio, et al.
Publicado: (2020)

Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice
por: Tubek, Stanisław, et al.
Publicado: (2021)

Antiplatelet therapy in patients with acute coronary syndromes and thrombocytopaenia: awaiting for evidence
por: Liga, Riccardo, et al.
Publicado: (2021)

Emerging antiplatelet agents, differential pharmacology, and clinical utility
por: Das, Pranab, et al.
Publicado: (2010)

Antiplatelet agents and proton pump inhibitors – personalizing treatment
por: Lin, Eugene, et al.
Publicado: (2010)

Ticagrelor: The first approved reversible oral antiplatelet agent
por: Goel, Divya
Publicado: (2013)

Antiplatelet/Anticoagulant Agents and Chronic Subdural Hematoma in the Elderly
por: De Bonis, Pasquale, et al.
Publicado: (2013)

Role of sodium tungstate as a potential antiplatelet agent
por: Fernández-Ruiz, Rebeca, et al.
Publicado: (2015)

Gastrointestinal endoscopy in patients on anticoagulant therapy and antiplatelet agents
por: Zullo, Angelo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b6st9ebtebqlh7kmt7clab9tg6